Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands

Introduction: Monoclonal antibody (mAb) L8A4 binds specifically to the epidermal growth factor receptor variant Ill (EGFRvIII) that is present on gliomas but not on normal tissues, and is internalized rapidly after receptor binding. Because of the short range of its beta-emissions, labeling this mAb with Lu-177 would be an attractive approach for the treatment of residual tumor margins remaining after surgical debulking of brain tumors. Materials and Methods: L8A4 mAb was labeled with Lu-177 using the acyclic ligands [(R)-2-amino-3-(4-isothiocyanatophenyl)propyl]trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid (CHX-A ''-DTPA) and 2-(4-isothiocyanatobenzyl)-6-methyldiethylene-triaminepentaacetic acid (1B4M-DTPA), and the macrocyclic ligands S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (C-DOTA) and (1-(5-isothiocyanato-2-methoxyphenyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (MeO-DOTA). Paired-label tissue distribution experiments were performed in athymic mice bearing subcutaneous EGFRvIII-expressing U87.Delta EGER glioma xenografts over a period of 1 to 8 days to directly compare Lu-177-labeled L8A4 to L8A4 labeled with I-125 using N-succinimidyl 4-guanidinomethyl-3[I-125]iodobenzoate ([I-125]SGMIB). Results: Except with C-DOTA, tumor uptake for the Lu-177-labeled mAb was significantly higher than the co-administered radioiodinated preparation; however, this was also the case for spleen, liver, bone and kidneys. Tumor/normal tissue ratios for Lu-177-1B4M-DTPA-L8A4 and, to an even greater extent, Lu-177-MeO-DOTA-L8A4 were higher than those for [I-125]SGMIB-L8A4 in most other tissues. Conclusions: Tumor and normal tissue distribution patterns for this anti-EGFRvIII mAb were dependent on the nature of the bifunctional chelate used for Lu-177 labeling. Optimal results were obtained with 1B4M-DTPA and MeO-DOTA, suggesting no clear advantage for acyclic vs. macrocyclic ligands for this application. (C) 2010 Elsevier Inc. All rights reserved.